河北医学2025，Vol.31Issue(5)：871-876,6.DOI:10.3969/j.issn.1006-6233.2025.05.030
CalliSpheres载药微球-支气管动脉化疗栓塞联合免疫治疗晚期非小细胞肺癌患者的效果观察
Clinical Observation of CalliSpheres Drug-Eluting Bead Bronchial Artery Chemoembolization(DEB-BACE)Combined with Immunotherapy in Advanced Non-Small Cell Lung Cancer
摘要
Abstract
Objective:To observe the efficacy of CalliSpheres drug-eluting bead bronchial artery chemo-embolization(DEB-BACE)combined with immunotherapy in advanced non-small cell lung cancer(NSCLC)patients.Methods:A retrospective analysis was performed on 142 advanced NSCLC patients admitted to our hospital from January 2020 to April 2023.Patients were divided into a control group(systemic chemotherapy combined with immunotherapy)and an observation group(CalliSpheres DEB-BACE combined with immuno-therapy).Propensity score matching(caliper value set to 0.01,1∶1 matching)was used,and 71 patients with comparable baseline data were finally included in each group.The efficacy on solid tumors,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA-125),cytokeratin fragment anti-gen 21-1(CYFRA21-1)]before and after treatment,T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),drug-related adverse reactions,and 1-year follow-up outcomes(progression-free survival,overall survival)were compared between the two groups.Results:The objective response rate(ORR)and disease control rate(DCR)in the observation group were 45.07%and 80.28%,respectively,significantly higher than 23.35%and 64.79%in the control group(P<0.05).Before treatment,there were no significant differences in CEA,CA125,and CYFRA21-1 levels between the two groups(P>0.05).After treatment,these markers de-creased in both groups(P<0.05),with greater reductions observed in the observation group(P<0.05).Be-fore treatment,CD4+,CD3+,and CD4+/CD8+levels showed no significant differences(P>0.05).After treatment,CD4+,CD3+,and CD4+/CD8+levels decreased in the observation group(P<0.05),with smaller changes compared to the control group(P>0.05).The incidence of bone marrow suppression was lower in the observation group(P<0.05).At 1-year follow-up,the observation group had a progression-free survival(PFS)of(10.12±0.31)months and an overall survival(OS)of(11.32±0.16)months,significantly better than the control group's PFS of(8.56±0.38)months and OS of(10.42±0.27)months(log rank χ2=6.416,P<0.05;log rank χ2=4.120,P=0.042).Conclusion:CalliSpheres DEB-BACE combined with im-munotherapy is safe and effective for advanced NSCLC patients.关键词
非小细胞肺癌/载药微球/支气管动脉化疗栓塞/实体瘤疗效/不良反应Key words
Non-small cell lung cancer/Drug-eluting beads/Transcatheter arterial chemoembo-lization/Solid tumor efficacy/Adverse reactions引用本文复制引用
占明,张弭,张浩宇,宋新宇..CalliSpheres载药微球-支气管动脉化疗栓塞联合免疫治疗晚期非小细胞肺癌患者的效果观察[J].河北医学,2025,31(5):871-876,6.基金项目
湖北省科技厅重点研发项目,(编号:2022BCE031) （编号:2022BCE031）
